Verve Therapeutics, Inc.

NasdaqGS:VERV Stok Raporu

Piyasa değeri: US$449.6m

Verve Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Verve Therapeutics CEO'su Sek Kathiresan, Jul2019 tarihinde atandı, in görev süresi 5.33 yıldır. in toplam yıllık tazminatı $ 9.32M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.4% maaş ve 93.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.8% ine doğrudan sahiptir ve bu hisseler $ 3.57M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3 yıl ve 3.5 yıldır.

Anahtar bilgiler

Sek Kathiresan

İcra Kurulu Başkanı

US$9.3m

Toplam tazminat

CEO maaş yüzdesi6.4%
CEO görev süresi5.3yrs
CEO sahipliği0.8%
Yönetim ortalama görev süresi3yrs
Yönetim Kurulu ortalama görev süresi3.5yrs

Son yönetim güncellemeleri

Recent updates

Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio

Aug 30

Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78

Aug 10
Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Jul 12
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Why Verve Therapeutics Deserves A Spot On Your Watchlist

Jun 13

Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

May 14
Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 12
The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

Apr 03

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 28
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Verve's Proof-Of-Concept Data Doesn't Inspire Confidence

Feb 13

Vectoring In On Verve Therapeutics

Jan 14

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Jun 07
Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 24
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Nov 09
We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Verve Therapeutics: Cathie Wood Adds To ARKK

Sep 20

Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate

Aug 23

Verve Therapeutics falls postmarket on $200M stock offering

Jul 20

More CRISPR In Human Subjects

Jul 14

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

May 11
Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Verve Therapeutics: Early-Stage Biotech With A Large Market

Apr 16

Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Jan 31
Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing

Aug 24

Verve Therapeutics jumps 75% in its first day of trading

Jun 17

CEO Tazminat Analizi

Sek Kathiresan'un ücretlendirmesi Verve Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$197m

Jun 30 2024n/an/a

-US$193m

Mar 31 2024n/an/a

-US$197m

Dec 31 2023US$9mUS$597k

-US$200m

Sep 30 2023n/an/a

-US$193m

Jun 30 2023n/an/a

-US$192m

Mar 31 2023n/an/a

-US$179m

Dec 31 2022US$8mUS$571k

-US$157m

Sep 30 2022n/an/a

-US$148m

Jun 30 2022n/an/a

-US$125m

Mar 31 2022n/an/a

-US$137m

Dec 31 2021US$6mUS$519k

-US$120m

Sep 30 2021n/an/a

-US$113m

Jun 30 2021n/an/a

-US$99m

Mar 31 2021n/an/a

-US$53m

Dec 31 2020US$2mUS$480k

-US$46m

Tazminat ve Piyasa: Sek 'nin toplam tazminatı ($USD 9.32M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.11M ).

Tazminat ve Kazançlar: Sek şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Sek Kathiresan (52 yo)

5.3yrs

Görev süresi

US$9,319,782

Tazminat

Dr. Sekar Kathiresan, M.D., also known as Sek, is Independent Director at Relay Therapeutics, Inc. since July 2022. He is a Founder at Maze Therapeutics, Inc and Director from September 2022. He is Co-Foun...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Sekar Kathiresan
Co-Founder5.3yrsUS$9.32m0.80%
$ 3.6m
Allison Dorval
CFO & Principal Accounting Officer3yrsUS$3.48m0.0048%
$ 21.6k
Andrew Ashe
President6.3yrsUS$3.32m0.40%
$ 1.8m
Kiran Musunuru
Co-Founderno dataVeri yokVeri yok
J. Joung
Co-Founderno dataVeri yokVeri yok
Anthony Philippakis
Co-Founder & Scientific Advisory Board Memberno dataUS$7.97kVeri yok
Barry Ticho
Co-Founderno dataVeri yokVeri yok
Issi Rozen
Co-Founder & Strategic Advisorno dataVeri yokVeri yok
Troy Lister
Chief Scientific Officerless than a yearVeri yok0.0021%
$ 9.6k
Joan Nickerson
Chief Administrative Officer1.8yrsVeri yok0.010%
$ 46.0k
Jennifer Robinson
Vice President of Investor Relations & Corporate Communications3yrsVeri yokVeri yok
Kaitlin Duffy
Executive Director of Human Resources1.8yrsVeri yokVeri yok

3.0yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: VERV 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Sekar Kathiresan
Co-Founder5.3yrsUS$9.32m0.80%
$ 3.6m
Anthony Philippakis
Co-Founder & Scientific Advisory Board Member3.2yrsUS$7.97kVeri yok
Burt Adelman
Co-Founder & Independent Chairman of the Board6.8yrsUS$451.88k0.51%
$ 2.3m
Daniel Rader
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Eugene Braunwald
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Michael MacLean
Independent Director3.5yrsUS$521.07k0%
$ 0
Sheila Mikhail
Independent Director3.6yrsUS$412.38k0%
$ 0
Lonnel Coats
Independent Director2.3yrsUS$407.38k0%
$ 0
Jodie Morrison
Directorless than a yearVeri yokVeri yok
Krishna Yeshwant
Independent Director6.3yrsUS$410.88k0%
$ 0
Alexander Cumbo
Independent Director2.4yrsUS$405.88k0%
$ 0
Andrew Geall
Member of Scientific Advisory Boardno dataVeri yokVeri yok

3.5yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: VERV 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.5 yıldır).